# acasunlimab Acasunlimab sees a surge in community interest with a 134% increase in engagements over [--] months, though recent 24-hour activity shows a dip. Creator activity is also up significantly, indicating a growing buzz around this bispecific antibody. ### About acasunlimab Acasunlimab is a bispecific antibody developed for cancer immunotherapy. ### Insights - acasunlimab engagements is up 33.96% from the previous week. ### Engagements: [--] (24h)  [Engagements 24-Hour Time-Series Raw Data](/topic/acasunlimab/time-series/interactions.tsv) Current Value: [--] Daily Average: [---] [--] Week: [--] +34% [--] Month: [---] -97% [--] Months: [------] +151% [--] Year: [------] -56% 1-Year High: [-----] on 2025-12-29 1-Year Low: [--] on 2025-04-07 Engagements by network (24h): News: [--] X: [--] ### Mentions: [--] (24h)  [Mentions 24-Hour Time-Series Raw Data](/topic/acasunlimab/time-series/posts_active.tsv) Current Value: [--] Daily Average: [--] [--] Week: [--] -27% [--] Month: [--] -38% [--] Months: [---] +445% [--] Year: [---] +15% 1-Year High: [--] on 2025-09-25 1-Year Low: [--] on 2025-02-15 Mentions by network (24h): News: [--] X: [--] ### Creators: [--] (24h)  [Creators 24-Hour Time-Series Raw Data](/topic/acasunlimab/time-series/contributors_active.tsv) [--] unique social accounts have posts mentioning acasunlimab in the last [--] hours which is down 17% from [--] in the previous [--] hours Daily Average: [--] [--] Week: [--] -20% [--] Month: [--] -29% [--] Months: [--] +380% [--] Year: [--] +13% 1-Year High: [--] on 2025-12-30 1-Year Low: [--] on 2025-02-15 ### Sentiment: %  [Sentiment 24-Hour Time-Series Raw Data](/topic/acasunlimab/time-series/sentiment.tsv) Current Value: % Daily Average: 82% [--] Week: 67% no change [--] Month: 67% -13% [--] Months: 67% +7% [--] Year: 67% -33% 1-Year High: 100% on 2025-10-07 1-Year Low: 33% on 2025-10-03 Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
Acasunlimab sees a surge in community interest with a 134% increase in engagements over [--] months, though recent 24-hour activity shows a dip. Creator activity is also up significantly, indicating a growing buzz around this bispecific antibody.
Acasunlimab is a bispecific antibody developed for cancer immunotherapy.
Engagements 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [---]
[--] Week: [--] +34%
[--] Month: [---] -97%
[--] Months: [------] +151%
[--] Year: [------] -56%
1-Year High: [-----] on 2025-12-29
1-Year Low: [--] on 2025-04-07
Engagements by network (24h): News: [--] X: [--]
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Week: [--] -27%
[--] Month: [--] -38%
[--] Months: [---] +445%
[--] Year: [---] +15%
1-Year High: [--] on 2025-09-25
1-Year Low: [--] on 2025-02-15
Mentions by network (24h): News: [--] X: [--]
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning acasunlimab in the last [--] hours which is down 17% from [--] in the previous [--] hours
Daily Average: [--]
[--] Week: [--] -20%
[--] Month: [--] -29%
[--] Months: [--] +380%
[--] Year: [--] +13%
1-Year High: [--] on 2025-12-30
1-Year Low: [--] on 2025-02-15
Sentiment 24-Hour Time-Series Raw Data
Current Value: %
Daily Average: 82%
[--] Week: 67% no change
[--] Month: 67% -13%
[--] Months: 67% +7%
[--] Year: 67% -33%
1-Year High: 100% on 2025-10-07
1-Year Low: 33% on 2025-10-03
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
/topic/acasunlimab